P50 gating in deficit and nondeficit schizophrenia

Schizophrenia Research

Volumn 119, Issue 1-3, 2010, Pages 183-190

  Santos, José Luis ^a   Sánchez Morla, Eva María ^a,b   Aparicio, Ana ^a   García Jiménez, María Ángeles ^a   Villanueva, Clara ^a   Martínez Vizcaíno, Vicente ^c   Arango, Celso ^d  

^a HOSPITAL VIRGEN DE LA LUZ   (Spain)

^b HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^c UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Auditory evoked potentials; Deficit syndrome; Functional outcome; Information processing; Negative symptoms

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; BIPERIDEN; CLOZAPINE; NEUROLEPTIC AGENT; PROTEIN P50;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEFICIT SCHIZOPHRENIA; DEMOGRAPHY; DISEASE DURATION; EDUCATION; EVOKED AUDITORY RESPONSE; FEMALE; HUMAN; MALE; NONDEFICIT SCHIZOPHRENIA; ONSET AGE; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SCHIZOPHRENIA; SENSORY GATING; SMOKING;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CEREBRAL CORTEX; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS, AUDITORY; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVE NET; PROGNOSIS; PSYCHIATRIC STATUS RATING SCALES; REFERENCE VALUES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SENSORY GATING; SIGNAL PROCESSING, COMPUTER-ASSISTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77952675658     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.01.010     Document Type: Article

References (77)

1. Adler L.E., Pachtman E., Franks R.D., Pecevich M., Waldo M.C., Freedman R. Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol. Psychiatry 1982, 17:639-654.
2. Adler L.E., Waldo M.C., Tatcher A., Cawthra E., Baker N., Freedman R. Lack of relationship of auditory gating defects to negative symptoms in schizophrenia. Schizophr. Res. 1990, 3:131-138.
3. Adler L.E., Olincy A., Cawthra E.M., McRae K.A., Harris J.G., Nagamoto H.T., Waldo M.C., Hall M.H., Bowles A., Woodward L., Ross R.G., Freedman R. Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. Am. J. Psychiatry 2004, 161:1822-1828.
4. Arango C., Kirkpatrick B., Buchanan R.W. Neurological signs and the heterogeneity of schizophrenia. Am. J. Psychiatry 2000, 157:560-565.
5. Arango C., Summerfelt A., Buchanan R.W. Olanzapine effects on auditory sensory gating in schizophrenia. Am. J. Psychiatry 2003, 160:2066-2068.
6. Arango C., McMahon R.P., Lefkowitz D.M., Pearlson G., Kirkpatrick B., Buchanan R.W. Patterns of cranial, brain and sulcal CSF volumes in male and female deficit and nondeficit patients with schizophrenia. Psychiatry Res. 2008, 162:91-100.
7. Arnfred S.M., Chen A.C. Exploration of somatosensory P50 gating in schizophrenia spectrum patients: reduced P50 amplitude correlates to social anhedonia. Psychiatry Res. 2004, 125:147-160.
8. Arnfred S.M., Chen A.C., Glenthøj B.Y., Hemmingsen R.P. Normal P50 gating in unmedicated schizophrenia outpatients. Am. J. Psychiatry 2003, 160:2236-2238.
9. Bernardo M., Fernández-Egea E., Torras A., Gutiérrez F., Ahuir M., Arango C. Adaptation and validation into Spanish of Schedule for the Deficit Syndrome. Med. Clin. (Barc). 2007, 129:91-93.
10. Boutros N.N. Lack of blinding in gating studies (letter to the editor). Schizophr. Res. 2008, 103:336.
11. Boutros N.N., Overall J., Zouridakis G. Test-retest reliability of the P50 mid-latency auditory evoked response. Psychiatry Res. 1991, 39:181-192.
12. Boutros N.N., Zouridakis G., Rustin T., Peabody C., Warner D. The P50 component of the auditory evoked potential and subtypes of schizophrenia. Psychiatry Res. 1993, 47:243-254.
13. Boutros N.N., Korzyukov O., Jansen B., Feingold A., Bell M. Sensory gating deficits during mid-latency phase of information processing in medicated schizophrenia patients. Psychiatry Res. 2004, 126:203-215.
14. Boutros N.N., Korzyuko O., Oliwa O., Feingold A., Campbell D., McClain-Furmanski D., Struve F., Jansen B.H. Morphological and latency abnormalities of the mid-latency auditory evoked responses in schizophrenia: a preliminary report. Schizophr. Res. 2004, 70:303-313.
15. Boutros N.N., Broskhaus-Dumke A., Gjini K., Vedeniapin A., Elfakhani M., Burroughs S., Keshavan M. Sensory-gating deficit of the N100 mid-latency auditory evoked potential in medicated schizophrenia patients. Schizophr. Res. 2009, 113:339-346.
16. Braff D.L., Geyer M.A. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch. Gen. Psychiatry 1990, 47:181-188.
17. Braff D.L., Light G.A. Preattentional and attentional cognitive deficits as targets for treating schizophrenia. Psychopharmacology 2004, 174(1):75-85.
18. Braff D.L., Light G.A., Swerdlow N.R. Prepulse inhibition and P50 suppression are both deficient but not correlated in schizophrenia patients. Biol. Psychiatry 2007, 61:1204-1207.
19. Bramon E., Rabe-Hesketh S., Sham P., Murray R.M., Frangou S. Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophr. Res. 2004, 70:315-329.
20. Brazo P., Marié R.M., Halbecq I., Benali K., Segard L., Delamillieure P., Langlois-Théry S., Van Der Elst A., Thibaut F., Petit M., Dollfus S. Cognitive patterns in subtypes of schizophrenia. Eur. Psychiatr. 2002, 17:155-162.
21. Buchanan R.W. Persistent negative symptoms in schizophrenia: an overview. Schizophr. Bull. 2007, 33:1013-1022.
22. Buchanan R.W., Kirkpatrick B., Heinrichs D.W., Carpenter W.T. Clinical correlates of the deficit syndrome of schizophrenia. Am. J. Psychiatry 1990, 147:290-294.
23. Buchanan R.W., Strauss M.E., Kirkpatrick B., Holstein C., Breier A., Carpenter W.T. Neuropsychological impairments in deficit vs nondeficit forms of schizophrenia. Arch. Gen. Psychiatry 1994, 51:804-811.
24. Carpenter W.T., Heinrichs D.W., Alphs L.D. Treatment of negative symptoms. Schizophr. Bull. 1985, 11:440-452.
25. Carpenter W.T., Heinrichs D.W., Wagman A.M. Deficit and nondeficit forms of schizophrenia: the concept. Am. J. Psychiatry 1988, 145:578-583.
26. Carpenter W.T., Buchanan R.W., Kirkpatrick B., Tamminga C., Wood F. Strong inference, theory testing, and the neuroanatomy of schizophrenia. Arch. Gen. Psychiatry 1993, 50:825-831.
27. Clementz B.A., Blumenfeld L.D. Multichannel electroencephalographic assessment of auditory evoked response suppression in schizophrenia. Exp Brain Res. 2001, 139:377-390.
28. Clementz B.A., Geyer M.A., Braff D.L. Poor P50 suppression among schizophrenia patients and their first-degree biological relatives. Am. J. Psychiatry 1998, 155:1691-1694.
29. Cohen A.S., Saperstein A.M., Gold J.M., Kirkpatrick B., Carpenter W.T., Buchanan R.W. Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date. Schizophr. Bull. 2007, 33:1201-1212.
30. de Wilde O.M., Bour L.J., Dingemans P.M., Koelman J.H., Linszen D.H. A meta-analysis of P50 studies in patients with schizophrenia and relatives: differences in methodology between research groups. Schizophr. Res. 2007, 97:137-151.
31. Erwin R.J., Turetsky B.I., Moberg P., Gur R.C., Gur R.E. P50 abnormalities in schizophrenia: relationship to clinical and neuropsychological indices of attention. Schizophr. Res. 1998, 33:157-167.
32. Freedman R., Adler L.E., Waldo M.C., Pachtman E., Franks R.D. Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: comparison of medicated and drug-free patients. Biol. Psychiatry 1983, 18:537-551.
33. Freedman R., Adler L.E., Gerhardt G.A., Waldo M., Baker N., Rose G.M., Drebing C., Nagamoto H., Bicford-Wimer P., Franks R. Neurobiological studies of sensory gating in schizophrenia. Schizophr. Bull. 1987, 13:669-678.
34. Fuerst D.R., Gallinat J., Boutros N.N. Range of sensory gating values and test-retest reliability in normal subjects. Psychophysiology 2007, 44:620-626.
35. Galderisi S., Maj M., Mucci A., Cassano G.B., Invernizzi G., Rossi A., Vita A., Dell'Osso L., Daneluzzo E., Pini S. Historical, psychopathological, neurological, and neuropsychological aspects of deficit schizophrenia: a multicenter study. Am. J. Psychiatry 2002, 159:983-990.
36. Galderisi S., Quarantelli M., Volpe U., Mucci A., Cassano G.B., Invernizzi G., Rossi A., Vita A., Pini S., Cassano P., Daneluzzo E., De Peri L., Stratta P., Brunetti A., Maj M. Patterns of structural MRI abnormalities in deficit and nondeficit schizophrenia. Schizophr. Bull. 2008, 34:393-401.
37. Gonul A.S., Kula M., Esel E., Tutus A., Sofuoglu S. Tc-99m HMPAO SPECT study of regional cerebral blood flow in drug-free schizophrenic patients with deficit and non deficit syndrome. Psychiatry Res. 2003, 123:199-205.
38. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry 1996, 153:321-330.
39. Green M.F., Kern R.S., Braff D.L., Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?. Schizophr. Bull. 2000, 26:119-136.
40. Griffith J., Hoffer L.D., Adler L.E., Zerbe G.O., Freedman R. Effects of sound intensity on a midlatency evoked response to repeated auditory stimuli in schizophrenic and normal subjects. Psychophysiology 1995, 32(5):460-466.
41. Guterman Y., Josiassen R.C. Sensory gating deviance in schizophrenia in the context of task related effects. Int. J. Psychophysiol. 1994, 8:1-12.
42. Heinrichs D.W., Hanlon T.E., Carpenter W.T. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr. Bull. 1984, 10:388-398.
43. Hong X., Chan R.C., Zhuang X., Jiang T., Wan X., Wang J., Xiao B., Zhou H., Jiang L., Weng B. Neuroleptic effects on P50 sensory gating in patients with first-episode never-medicated schizophrenia. Schizophr. Res. 2009, 108(1-3):151-157.
44. Jin Y., Bunney W.E., Sandman C.A., Patterson J.V., Fleming K., Moenter J.R., Kalali A.H., Hetrick W.P., Potkin S.G. Is P50 suppression a measure of sensory gating in schizophrenia?. Biol. Psychiatry 1998, 43:873-878.
45. Judd L.L., McAdams L., Budnick B., Braff D.L. Sensory gating deficits in schizophrenia: new results. Am. J. Psychiatry 1992, 149:488-493.
46. Kathmann N., Engel R.R. Sensory gating in normals and schizophrenics: a failure to find strong P50 suppression in normals. Biol. Psychiatry 1990, 27:1216-1226.
47. Kawakubo Y., Kamio S., Nose T., Iwanami A., Nakagome K., Fukuda M., Kato N., Rogers M.A., Kasai K. Phonetic mismatch negativity predicts social skills acquisition in schizophrenia. Psychiatry Res. 2007, 30(152):261-265.
48. Kay S.R., Fisbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
49. Kirkpatrick B., Buchanan R.W., McKenney P.D., Alphs L.D., Carpenter W.T. The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res. 1989, 30:119-123.
50. Kirkpatrick B., Buchanan R.W., Ross D.E., Carpenter W.T. A separate disease within the syndrome of schizophrenia. Arch. Gen. Psychiatry 2001, 58:165-171.
51. Kirkpatrick B., Fernández-Egea E., García-Rizo C., Bernardo M. Differences in glucose tolerance between deficit and non-deficit schizophrenia. Schizophr. Res. 2009, 107(2-3):122-127.
52. Light G.A., Braff D.L. Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Arch. Gen. Psychiatry 2005, 62:127-136.
53. Light G.A., Braff D.L. Stability of mismatch negativity deficits and their relationship to functional impairments in chronic schizophrenia. Am. J. Psychiatry 2005, 162:1741-1743.
54. Light G.A., Geyer M.A., Clementz B.A., Cadenhead K.S., Braff D.L. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. Am. J. Psychiatry 2000, 157:767-771.
55. Louchart-de la Chapelle S., Levillain D., Ménard J.F., Van der Elst A., Allio G., Haouzir S., Dollfus S., Campion D., Thibaut F. P50 inhibitory gating deficit is correlated with the negative symptomatology of schizophrenia. Psychiatry Res. 2005, 136:27-34.
56. Meisenzahl E.M., Frodl T., Müller D., Schmitt G., Gallinat J., Zetzsche T., Marcuse A., Juckel G., Leinsinger G., Hahn K., Möller H.J., Hegerl U. Superior temporal gyrus and P300 in schizophrenia: a combined ERP/structural magnetic resonance imaging investigation. J. Psychiatr. Res. 2004, 38:153-162.
57. Mucci A., Galderisi S., Kirkpatrick B., Bucci P., Volpe U., Merlotti E., Centanaro F., Catapano F., Maj M. Double dissociation of N1 and P3 abnormalities in deficit and nondeficit schizophrenia. Schizophr. Res. 2007, 92:252-261.
58. Nagamoto H.T., Adler L.E., Waldo M.C., Freedman R. Sensory gating in schizophrenics and normal controls: effects of changing stimulation interval. Biol. Psychiatry 1989, 25:549-561.
59. Nagamoto H.T., Adler L.E., Hea R.A., Griffith J.M., McRae K.A., Freedman R. Gating of auditory P50 in schizophrenics: unique effects of clozapine. Biol. Psychiatry 1996, 40:181-188.
60. Nagamoto H.T., Adler L.E., McRae K.A., Huettl P., Cawthra E., Gerhardt G., Hea R., Griffith J. Auditory P50 in schizophrenics on clozapine: improving gating parallels clinical improvement and changes in plasma 3-methoxy-4-hydroxyphenylglycol. Neuropsychobiology 1999, 39(1):10-17.
61. Patterson J.V., Hetrick W.P., Boutros N.N., Jin Y., Sandman C., Stern H., Potkin S., Bunney W.E. P50 sensory gating ratios in schizophrenics and controls: a review and data analysis. Psychiatry Res. 2008, 158:226-247.
62. Peralta V., Cuesta M.J. Psychometric properties of the Positive and Negative Syndrome Scale (PANSS) in schizophrenia. Psychiatry Res. 1994, 53:31-40.
63. Potter D., Summerfelt A., Gold J., Buchanan R.W. Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. Schizophr. Bull. 2006, 32:692-700.
64. Ringel T.M., Heidrich A., Jacob C.P., Pfuhlmann B., Stoeber G., Fallgatter A.J. Sensory gating in a subtype of chronic schizophrenic patients. Psychiatry Res. 2004, 125:237-245.
65. Rodríguez-Fornells A., Rodríguez-Martínez A., Jarne A., Soler R., Miarons R., Grau A. Estudio factorial y adaptación de la Escala de Calidad de Vida de la Esquizofrenia (QLS). Rev. Psicol. Gen. Apl. 1995, 48:353-364.
66. Sánchez-Morla E.M., García-Jiménez M.A., Barabash A., Martínez-Vizcaíno V., Mena J., Cabranes-Díaz J.A., Baca-Baldomero E., Santos J.L. P50 sensory gating deficit is a common marker of vulnerability to bipolar disorder and schizophrenia. Acta Psychiatr. Scand. 2008, 117:313-318.
67. Sánchez-Morla E.M., Santos J.L., Aparicio A., García-Jiménez M.A., Villanueva C., Martínez-Vizcaíno V., Arango C. Antipsychotics effects on auditory sensory gating in schizophrenia patients. Eur. Neuropsychopharmacol. 2009, 19:905-909.
68. Smith D.A., Boutros N.N., Schwarzkopf S.B. Reliability of P50 auditory event-related potential indices of sensory gating. Psychophysiology 1994, 31:495-502.
69. Straumanis J.J., Shagass C., Roemer R.A. Influence of antipsychotic and antidepressant drugs on evoked potential correlates of psychosis. Biol. Psychiatry 1982, 17:1101-1122.
70. Swerdlow N.R., Light G.A., Cadenhead K.S., Sprock J., Hsieh M.H., Braff D.L. Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function. Arch. Gen. Psychiatry 2006, 63:1325-1335.
71. Swerdlow N.R., Weber M., Qu Y., Light G.A., Braff D.L. Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology 2008, 199:331-388.
72. Thaker G.K. Neurophysiological endophenotypes across bipolar and schizophrenia psychosis. Schizophr. Bull. 2008, 34:760-773.
73. Turetsky B.I., Colbalth E.A., Gur R.E. P300 subcomponent abnormalities in schizophrenia: I. Physiological evidence for gender and subtype specific differences in regional pathology. Biol. Psychiatry 1998, 43:84-96.
74. Vaiva G., Cottencin O., Llorca P.M., Devos P., Dupont S., Mazas O., Rascle C., Thomas P., Steinling M., Goudemand M. Regional cerebral blood flow in deficit/nondeficit types of schizophrenia according to SDS criteria. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26:481-485.
75. Ward P.B., Hoffer L.D., Liebert B.J., Catts S.V., O'Donnell M., Adler L.E. Replication of a P50 auditory gating deficit in Australian patients with schizophrenia. Psychiatry Res. 1996, 64:121-135.
76. White P.M., Yee C.M. P50 sensitivity to physical and psychological state influences. Psychophysiology 2006, 43:320-328.
77. Yee C.M., Nuechterlein K.H., Morris S.E., White P.M. P50 suppression in recent-onset schizophrenia: clinical correlates and risperidone effects. J. Abnorm. Psychology 1998, 107:691-698.